Andy Kidd, Aptinyx CEO
‘The placebo caught up’: Months after diabetic nerve pain fail, Aptinyx sees another pain trial fall through
In 2019, Aptinyx’s stock cratered after it reported that its lead candidate failed a diabetic nerve pain trial. After some
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
